MARKET

NBSE

NBSE

NeuBase Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.910
+0.020
+0.41%
Closed 16:00 05/11 EDT
OPEN
4.810
PREV CLOSE
4.890
HIGH
5.02
LOW
4.700
VOLUME
337.20K
TURNOVER
--
52 WEEK HIGH
12.89
52 WEEK LOW
4.700
MARKET CAP
158.99M
P/E (TTM)
-6.0305
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Benzinga · 14h ago
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 17h ago
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 4d ago
Insider Buying: The NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Independent Director Just Bought 120% More Shares
Even if it's not a huge purchase, we think it was good to see that Dov Goldstein, the Independent Director of NeuBase...
Simply Wall St. · 04/28 09:27
NeuBase Therapeutics to Present at the B. Riley Securities Virtual Neuroscience Conference
PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph....
GlobeNewswire · 04/27 13:00
Oppenheimer Thinks NeuBase Therapeutics’ Stock is Going to Recover
In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on NeuBase Therapeutics (NBSE), with a price target of $17.00. The
SmarterAnalyst · 04/27 00:15
NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the closing of its previousl...
GlobeNewswire · 04/26 21:01
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22)
Benzinga · 04/23 11:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBSE. Analyze the recent business situations of NeuBase Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBSE stock price target is 16.75 with a high estimate of 18.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 73
Institutional Holdings: 6.95M
% Owned: 21.46%
Shares Outstanding: 32.38M
TypeInstitutionsShares
Increased
20
226.40K
New
10
495.78K
Decreased
12
268.28K
Sold Out
7
251.60K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
President/Chief Executive Officer/Director
Dietrich Stephan
Chief Financial Officer/Treasurer/Secretary
Sam Backenroth
Chief Operating Officer
William Mann
Director
Gines Miralles
Chief Scientific Officer
Curt Bradshaw
Independent Director
Dov Goldstein
Independent Director
Franklyn Prendergast
Independent Director
Eric Richman
No Data
  • All
  • Financials
  • Insiders
More
About NBSE
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

Webull offers kinds of Neubase Therapeutics Inc stock information, including NASDAQ:NBSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBSE stock methods without spending real money on the virtual paper trading platform.